Assignee
BIONTECH US INC
US·7 granted patents·22 pending applications·9 citations·filing 2018–2025
Top patents by PatentIndex Score
29 records- 0191US11183272B2Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cellsBIONTECH US INC·Filed 2020·Granted Nov 23, 2021·5 cites·19 claims
- 0281US11793867B2Neoantigens and uses thereofBIONTECH US INC·Filed 2018·Granted Oct 24, 2023·2 cites·17 claims
- 0380US12258581B2T cell manufacturing compositions and methodsBIONTECH US INC·Filed 2021·Granted Mar 25, 2025·1 cites·21 claims
- 0478US12246067B2Neoantigens and uses thereofBIONTECH US INC·Filed 2019·Granted Mar 11, 2025·1 cites·19 claims
- 0577US2023405102A1Neoantigens and methods of their useBIONTECH US INC·Filed 2023·Application pending·0 cites
- 0677US2023414735A1Neoantigens and methods of their useBIONTECH US INC·Filed 2023·Application pending·0 cites
- 0771US2023384320A1Hla-based methods and compositions and uses thereofBIONTECH US INC·Filed 2023·Application pending·0 cites
- 0868US2024100139A1Neoantigens and uses thereofBIONTECH US INC·Filed 2023·Application pending·0 cites
- 0966US2022199198A1Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cellsBIONTECH US INC·Filed 2021·Application pending·0 cites
- 1063US2026048116A1Protein antigens and uses thereofBIONTECH US INC·Filed 2025·Application pending·0 cites
- 1162US2024156961A1Tissue-specific antigens for cancer immunotherapyBIONTECH US INC·Filed 2023·Application pending·0 cites
- 1260US12303561B2Protein antigens and uses thereofBIONTECH US INC·Filed 2018·Granted May 20, 2025·0 cites·24 claims
- 1360US2025188414A1T cell manufacturing compositions and methodsBIONTECH US INC·Filed 2025·Application pending·0 cites
- 1456US2025228945A1Neoantigens and uses thereofBIONTECH US INC·Filed 2025·Application pending·0 cites
- 1555US2026034201A1Combination therapy with neoantigen vaccineBIONTECH US INC·Filed 2023·Application pending·0 cites
- 1654US2023374455A1T cell manufacturing compositions and methodsBIONTECH US INC·Filed 2021·Application pending·0 cites
- 1753US11965892B2HLA-based methods and compositions and uses thereofBIONTECH US INC·Filed 2018·Granted Apr 23, 2024·0 cites·21 claims
- 1852US12331097B2T cell receptor constructs and uses thereofBIONTECH US INC·Filed 2019·Granted Jun 17, 2025·0 cites·17 claims
- 1951US2025195659A1T cell manufacturing compositions and methodsBIONTECH US INC·Filed 2022·Application pending·0 cites
- 2051US2023083931A1Coronavirus vaccines and methods of useBIONTECH US INC·Filed 2021·Application pending·0 cites
- 2151US2023398218A1Ras neoantigens and uses thereofBIONTECH US INC·Filed 2021·Application pending·0 cites
- 2250US2022282217A1Compositions and methods for preparing t cell compositions and uses thereofBIONTECH US INC·Filed 2020·Application pending·0 cites
- 2349US2026031189A1Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cellsBIONTECH US INC·Filed 2023·Application pending·0 cites
- 2448US2021386856A1Combination therapy with neoantigen vaccineBIONTECH US INC·Filed 2019·Application pending·0 cites
- 2548US2023141371A1Coronavirus vaccines and methods of useBIONTECH US INC·Filed 2021·Application pending·0 cites
- 2647US2021275657A1Neoantigens and uses thereofBIONTECH US INC·Filed 2019·Application pending·0 cites
- 2744US2022280621A1T cell manufacturing compositions and methodsBIONTECH US INC·Filed 2020·Application pending·0 cites
- 2842US2023000960A1Neoantigen compositions and uses thereofBIONTECH US INC·Filed 2020·Application pending·0 cites
- 2931US2022152176A1Cancer biomarkers for durable clinical benefitBIONTECH US INC·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →